An anti-aggregation agent of the present invention contains, as an anti-aggregation ingredient, at least one selected from the group consisting of polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 and combinations thereof. According to the present invention, in a container whose inner wall is treated with silicone oil, aggregation of a poorly water-soluble drug caused by the silicone oil can be prevented.

Disclosed are niclosamide formulations for use as antiviral therapy. The formulations disclosed herein may be used for treating a sexually-transmitted virus or a respiratory virus (e.g., coronavirus).

This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for treating post-acute sequelae of COVID-19 comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.

A process for producing an oxidized nanofibrillar cellulose hydrogel is disclosed, wherein the process comprises oxidizing cellulose pulp fibers in the presence of hypochlorite as an oxidant and a heterocyclic nitroxyl radical as a catalyst; and disintegrating the oxidized cellulose pulp fibers to obtain a nanofibrillar cellulose hydrogel; wherein all steps of the process after oxidizing are performed under aseptic conditions. An oxidized nanofibrillar cellulose hydrogel and a system for producing the same are also disclosed.

A process for producing an oxidized nanofibrillar cellulose hydrogel is disclosed, wherein the process comprises oxidizing cellulose pulp fibers in the presence of hypochlorite as an oxidant and a heterocyclic nitroxyl radical as a catalyst; and disintegrating the oxidized cellulose pulp fibers to obtain a nanofibrillar cellulose hydrogel; wherein all steps of the process after oxidizing are performed under aseptic conditions. An oxidized nanofibrillar cellulose hydrogel and a system for producing the same are also disclosed.

The present invention relates to a hydrogel formulation for delivering probiotics including a hydrogel, probiotics and zwitterionic buffer as an active ingredient, a composition for delivering probiotics comprising the same and a method of preparing the same, which adjust and maintain the internal pH of the hydrogel even in the gastric juice environment, thereby increasing the survival rate of the probiotics in the gastric juice and improving the delivery rate to the large intestine, by further adding zwitterionic buffer capable of maintaining pH to the hydrogel encapsulated with probiotics.

The present invention relates to a hydrogel formulation for delivering probiotics including a hydrogel, probiotics and zwitterionic buffer as an active ingredient, a composition for delivering probiotics comprising the same and a method of preparing the same, which adjust and maintain the internal pH of the hydrogel even in the gastric juice environment, thereby increasing the survival rate of the probiotics in the gastric juice and improving the delivery rate to the large intestine, by further adding zwitterionic buffer capable of maintaining pH to the hydrogel encapsulated with probiotics.

The present invention relates to a liquid pharmaceutical composition for oral administration in the form of suspension which comprises the combination of ibuprofen and phenylephrine, or a pharmaceutically acceptable salt thereof, as active substances, and hypromellose, xanthan gum, liquid maltitol, glycerine and water. The composition is stable, has good organoleptical properties and shows excellent pharmacokinetic profile, providing quick absorption of the drugs. The present invention also relates to the use of the composition for treating the symptoms of flu and common cold, particularly in adults and in children over 7 years.

The present invention relates to a liquid pharmaceutical composition for oral administration in the form of suspension which comprises the combination of ibuprofen and phenylephrine, or a pharmaceutically acceptable salt thereof, as active substances, and hypromellose, xanthan gum, liquid maltitol, glycerine and water. The composition is stable, has good organoleptical properties and shows excellent pharmacokinetic profile, providing quick absorption of the drugs. The present invention also relates to the use of the composition for treating the symptoms of flu and common cold, particularly in adults and in children over 7 years.

The present disclosure provides compositions and methods for acidic compositions for use in optimizing the genital microbiome of a user or sexual partners of that user. The compositions may comprise a prebiotic oligosaccharide, a metal co-factor, and an essential oil comprising bornyl acetate. The compositions support the genital microbiota and are useful for, for example, hydrating, lubricating, cleaning, and/or decreasing irritation or inflammation of the urogenital and/or anogenital region of a subject, and/or enhancing the beneficial genital microbiota of a subject. Such compositions are useful before, during, and/or after sexual and/or reproductive activity. Furthermore, the compositions may have minimal or beneficial effect on gametes.